Kamar Khalil, MacDougall Kira, Alsheikh Mira, Parylo Sara, Skaradinskiy Yevgeniy
Department of Internal Medicine, Zucker School of Medicine at Hofstra/Northwell at Staten Island University Hospital, New York, NY, USA.
Department of Hematology & Medical Oncology, Zucker School of Medicine at Hofstra/Northwell at Staten Island University Hospital, New York, NY, USA.
J Community Hosp Intern Med Perspect. 2021 Mar 23;11(2):269-272. doi: 10.1080/20009666.2021.1871802.
Eptifibatide is a glycoprotein (GP) IIb/IIIa receptor antagonist, used for the treatment of acute coronary syndrome with high-risk features or ongoing ischemia. Several case reports have described thrombocytopenia as a rare side effect of eptifibatide administration. The exact mechanism remains unclear but may be due to immune destruction of circulating platelets in the peripheral blood. We present the case of acute-onset severe thrombocytopenia in a 76-year-old female undergoing percutaneous coronary intervention.
依替巴肽是一种糖蛋白(GP)IIb/IIIa受体拮抗剂,用于治疗具有高危特征或持续缺血的急性冠状动脉综合征。几例病例报告描述了血小板减少症是依替巴肽给药的一种罕见副作用。确切机制尚不清楚,但可能是由于外周血中循环血小板的免疫破坏所致。我们报告了一例76岁接受经皮冠状动脉介入治疗的女性急性严重血小板减少症病例。